AIM ImmunoTech Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume443,981 shs
Average Volume1.92 million shs
Market Capitalization$109.06 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AIM News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

AIM ImmunoTech logo

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.40 out of 5 stars

Medical Sector

729th out of 2,096 stocks

Biological Products, Except Diagnostic Industry

97th out of 196 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AIM ImmunoTech (NYSE:AIM) Frequently Asked Questions

Is AIM ImmunoTech a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AIM ImmunoTech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AIM ImmunoTech stock.
View analyst ratings for AIM ImmunoTech
or view top-rated stocks.

What stocks does MarketBeat like better than AIM ImmunoTech?

Wall Street analysts have given AIM ImmunoTech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AIM ImmunoTech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AIM ImmunoTech's next earnings date?

AIM ImmunoTech is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for AIM ImmunoTech

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) posted its quarterly earnings data on Tuesday, May, 18th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The company had revenue of $0.03 million for the quarter. AIM ImmunoTech had a negative net margin of 9,718.49% and a negative trailing twelve-month return on equity of 23.90%.
View AIM ImmunoTech's earnings history

How has AIM ImmunoTech's stock been impacted by COVID-19 (Coronavirus)?

AIM ImmunoTech's stock was trading at $4.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AIM shares have decreased by 45.7% and is now trading at $2.28.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AIM?

2 brokerages have issued twelve-month target prices for AIM ImmunoTech's stock. Their forecasts range from $2.00 to $5.50. On average, they anticipate AIM ImmunoTech's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price.
View analysts' price targets for AIM ImmunoTech
or view top-rated stocks among Wall Street analysts.

Who are AIM ImmunoTech's key executives?

AIM ImmunoTech's management team includes the following people:
  • Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 68, Pay $1.52M)
  • Ms. Ellen M. Lintal, CFO & Chief Accounting Officer (Age 62, Pay $441.99k)
  • Mr. Peter W. Rodino III, Esq., J.D., COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 70, Pay $681.86k)
  • Dr. David R. Strayer, Chief Scientific Officer & Medical Director (Age 75)
  • Ann Marie E. Coverly, Director of Admin. & HR and Deputy Investor Relations Coordinator
  • Dr. Carol A. Smith, Chief Manufacturing Officer & Deputy Chief Scientific Officer (Age 70)
  • Julie Mierau, Controller
  • Dr. Ralph Christopher Cavalli, VP of QC & Manufacturing (Age 63)

Who are some of AIM ImmunoTech's key competitors?

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX).

What is AIM ImmunoTech's stock symbol?

AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."

Who are AIM ImmunoTech's major shareholders?

AIM ImmunoTech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Stanley (5.24%), BlackRock Inc. (2.05%), Renaissance Technologies LLC (1.00%), Geode Capital Management LLC (0.74%), Verition Fund Management LLC (0.23%) and Citadel Advisors LLC (0.22%). Company insiders that own AIM ImmunoTech stock include David R Strayer, Stewart Appelrouth, Thomas K Equels, Wayne S Springate and William M Mitchell.
View institutional ownership trends for AIM ImmunoTech

Which institutional investors are selling AIM ImmunoTech stock?

AIM stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for AIM ImmunoTech
or view top insider-selling stocks.

Which institutional investors are buying AIM ImmunoTech stock?

AIM stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, BlackRock Inc., Geode Capital Management LLC, Citadel Advisors LLC, HighTower Advisors LLC, GSA Capital Partners LLP, and Verition Fund Management LLC. Company insiders that have bought AIM ImmunoTech stock in the last two years include David R Strayer, Stewart Appelrouth, Thomas K Equels, Wayne S Springate, and William M Mitchell.
View insider buying and selling activity for AIM ImmunoTech
or or view top insider-buying stocks.

How do I buy shares of AIM ImmunoTech?

Shares of AIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AIM ImmunoTech's stock price today?

One share of AIM stock can currently be purchased for approximately $2.28.

How much money does AIM ImmunoTech make?

AIM ImmunoTech has a market capitalization of $109.06 million and generates $160,000.00 in revenue each year.

How many employees does AIM ImmunoTech have?

AIM ImmunoTech employs 21 workers across the globe.

What is AIM ImmunoTech's official website?

The official website for AIM ImmunoTech is aimimmuno.com.

Where are AIM ImmunoTech's headquarters?

AIM ImmunoTech is headquartered at 2117 SW HIGHWAY 484, OCALA FL, 34473.

How can I contact AIM ImmunoTech?

AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The company can be reached via phone at 352-448-7797 or via email at [email protected]

This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.